v3.19.3

Note 10 - Stock Options | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2019 | Dec. 31, 2018
Notes to Financial Statements |  |
Share-based Payment Arrangement [Text Block] | Note 10. Stock Options On May 3, 2019, in connection with the closing of the Merger, each outstanding Private Adynxx stock option, whether vested or unvested, was converted into a stock option to purchase shares of the Company’s common stock at the Exchange Ratio and, as a result, the Company issued options to purchase an aggregate of 690,058 shares of the Company’s common stock at exercise prices ranging from $1.11 to $3.06 per share. Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 shares of the post-Merger Company’s common stock at exercise prices ranging from $21.00 to $656.40 per share to former Alliqua option holders that were assumed as part of the merger. All Alliqua employees were terminated in connection with the Merger; however, such options have provisions that extend the expiration date beyond the employees’ termination date. A summary of the Company’s stock option activity during the six months ended June 30, 2019 is as follows (in thousands, except exercise prices):
|  | Number of Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life In Years |  | Intrinsic Value |
Outstanding, December 31, 2018 |  | 690 |  | $ | 2.76 |  |  |  |  |
Alliqua options assumed in Merger |  | 58 |  | 289.76 |  |  |  |  |
Exercised |  | — |  | — |  |  |  |  |
Cancelled |  | — |  | — |  |  |  |  |
Outstanding, June 30, 2019 |  | 748 |  | $ | 24.95 |  | 6.2 |  | $ | 188 |
Exercisable, June 30, 2019 |  | 530 |  | $ | 33.93 |  | 5.7 |  | $ | 188 |
A summary of the Company’s stock options as of June 30, 2019 is as follows (in thousands, except exercise prices):
|  | Options Outstanding |  | Options Exercisable |
Range of Exercise Price |  | Weighted Average Exercise Price |  | Outstanding Number of Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life In Years |  | Exercisable Number of Options |
$1.11 — $1.38 |  | $ 1.11 |  | 73 |  | $ 1.11 |  | 2.5 |  | 73 |
1.39 — 3.05 |  | 1.39 |  | 37 |  | 1.39 |  | 3.2 |  | 37 |
3.06 — 20.99 |  | 3.06 |  | 580 |  | 3.06 |  | 7.5 |  | 362 |
21.00 — 656.40 |  | 289.81 |  | 58 |  | 289.81 |  | 0.7 |  | 58 |
|  | $ 24.95 |  | 748 |  | $ 24.76 |  | 5.7 |  | 530 |
The Company did not grant any stock options to employees during the six months ended June 30, 2019. Stock-based compensation expense recorded in research and development and general and administrative expenses was $150,000 and $136,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years. Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $32,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months. | Note 9. Stock Option Plans In December 2010, the Company adopted the 2010 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (“ISOs”) or non-qualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The Company has 19,222,032 shares of common stock reserved for issuance under the Plan as of December 31, 2018. Options under the Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board of Directors provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Plan requires that options be exercised no later than 10 years after the grant. Options granted to employees generally vest ratably on a monthly basis over four years. The following table summarizes stock option activity under the Company’s stock plan and related information (in thousands, except exercise prices and years):
|  |  |  | Outstanding Options
|  |  |  |  |  |  |  |  | Weighted- |  |  |
|  |  |  |  |  | Weighted- |  | Average |  |  |
|  |  |  |  |  | Average |  | Remaining |  |  |
|  | Shares |  |  |  | Exercise |  | Contractual |  | Aggregate
|  | Available |  | Options |  | Price |  | Life |  | Intrinsic
|  | For Grant |  | Outstanding |  | Per Share |  | (in years) |  | Value(a)
Balance at December 31, 2016 |  | 5 |  | 19,222 |  | $ | 0.10 |  | 9.4 |  |  |
Balance at December 31, 2017 |  | 5 |  | 19,222 |  | $ | 0.10 |  | 8.4 |  | $ | 6,639
Balance at December 31, 2018 |  | 5 |  | 19,222 |  | $ | 0.10 |  | 7.4 |  | $ | 6,956
Vested and expected to vest as of December 31, 2018 |  |  |  | 19,222 |  | $ | 0.10 |  | 7.4 |  | $ | 6,956
Exercisable at December 31, 2018 |  |  |  | 11,146 |  | $ | 0.09 |  | 7.4 |  | $ | 4,119
​
| (a) |  | The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company’s common stock of $0.46 and $0.44 per share as of December 31, 2018 and 2017.
​The Company did not grant any common stock options to employees during the years ended December 31, 2017 and 2018. Stock-based compensation expense recorded in research and development and general and administrative expenses was $301,000 and $293,000 for the years ended December 31, 2017 and 2018, respectively. As of December 31, 2018, unrecognized stock-based compensation expense related to employees totaled approximately $531,000, which is expected to be recognized over approximately 2.0 years. Stock Options Granted to Non-Employees Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $16,000 for the years ended December 31, 2017 and 2018, respectively. As of December 31, 2018, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $48,000, which is expected to be recognized over a weighted-average period of nine months.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration